title: Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour.
abstract: Several recent studies have shown that reducing gamma-aminobutyric acid (GABA)-mediated neurotransmission retards extinction of aversive conditioning. However, relatively little is known about the effect of GABA on extinction of appetitively motivated tasks. We examined the effect of chlordiazepoxide (CDP), a classical benzodiazepine (BZ) and two novel subtype-selective BZs when administered to male C57Bl/6 mice during extinction following training on a discrete-trial fixed-ratio 5 (FR5) food reinforced lever-press procedure. Initially CDP had no effect, but after several extinction sessions CDP significantly facilitated extinction, i.e. slowed responding, compared with vehicle-treated mice. This effect was not due to drug accumulation because mice switched from vehicle treatment to CDP late in extinction showed facilitation immediately. Likewise, this effect could not be attributed to sedation because the dose of CDP used (15 mg/kg i.p.) did not suppress locomotor activity. The two novel subtype-selective BZ partial agonists, L-838417 and TP13, selectively facilitated extinction in similar fashion to CDP. The non-GABAergic anxiolytic buspirone was also tested and found to have similar effects when administered at a non-sedating dose. These studies demonstrate that GABA-mediated processes are important during extinction of an appetitively motivated task, but only after the animals have experienced several extinction sessions.
authors.affiliation: School of Psychology, University of Ulster, Shore Road, BT37 0QB, Northern Ireland, Newtownabbey, UK.
authors.forename: Ciara
authors.initials: C
authors.lastname: McCabe
authors.forename: David
authors.initials: D
authors.lastname: Shaw
authors.forename: John R
authors.initials: JR
authors.lastname: Atack
authors.forename: Leslie J
authors.initials: LJ
authors.lastname: Street
authors.forename: Keith A
authors.initials: KA
authors.lastname: Wafford
authors.forename: Gerard R
authors.initials: GR
authors.lastname: Dawson
authors.forename: David S
authors.initials: DS
authors.lastname: Reynolds
authors.forename: Julian C
authors.initials: JC
authors.lastname: Leslie
mesh_terms: D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects* / Q000502:physiology; D005108:Extinction, Psychological / Q000187:drug effects* / Q000502:physiology; D005464:Fluorobenzenes / Q000737:chemistry / Q000494:pharmacology; D018682:GABA Agents / Q000737:chemistry / Q000494:pharmacology*; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011963:Receptors, GABA-A / Q000502:physiology; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology
chemical_list: D005464:Fluorobenzenes; D018682:GABA Agents; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D014230:Triazoles; C409903:L 838,417